Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FP · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fluticasone propionate/salmeterol combination | EXPERIMENTAL | study drug |
| Fluticasone propionate | EXPERIMENTAL | study drug |
| Placebo | EXPERIMENTAL | placebo |
| FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | EXPERIMENTAL | FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) |
| FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM) | ACTIVE_COMPARATOR | FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM) |
| FP/SAL 250/50mcg BID plus placebo BID | PLACEBO_COMPARATOR | P/SAL 250/50mcg BID plus placebo BID |
| Name | Type | Description |
|---|---|---|
| FP 100mcg | DRUG | Once-daily dosing |
| FSC 100/50mcg | DRUG | Once-daily dosing |
| Placebo | DRUG | Once-daily dosing |
| FP/SAL 250/50mcg BID | DRUG | FP/SAL 250/50mcg BID |
| GSK2190915 200mg QD (AM) | DRUG | GSK2190915 200mg QD (AM) |
| GSK2190915 100mg QD (AM) | DRUG | GSK2190915 100mg QD (AM) |
| Montelukast 10mg QD (PM) | DRUG | Montelukast 10mg QD (PM) |
| Placebo tablets (2) (AM) | DRUG | Placebo tablets (2) (AM) |
| Placebo capsule (PM) | DRUG | Placebo capsule (PM) |
Inclusion Criteria: * Out-patients * Asthma diagnosis * Reversibility * Short-acting beta-agonist or asthma controlled medication use Exclusion Criteria: * Life-threatening asthma * Specified asthma medications * Chickenpox * Drug allergy * Respiratory infections * Tobacco use * Clinical laborato...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
FP is used for the treatment of asthma. It is a small molecule therapy in the respiratory therapeutic area. The clinical program for FP includes studies in patients with asthma, evaluating its use in combination with an inhaled corticosteroid and long acting beta agonist.
FP is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical trials evaluating FP in asthma.
FP is in Phase 3 clinical development for asthma. The program includes a completed Phase 3 trial and a completed Phase 2 trial. FP is investigational and has not been approved by the FDA for any indication.
FP has been studied in two completed clinical trials. NCT00920959 was a Phase 3 trial titled Advair Pediatric Once-Daily, which enrolled 908 participants with asthma. NCT01248975 was a Phase 2 trial evaluating the addition of GSK2190915 to mid-dose inhaled corticosteroid and long acting beta agonist combination treatment, enrolling 145 participants.